SMARCA4 and lung carcinoma: Typically diagnosed at an advanced stage, SMARCA4‐UT exhibit poor responses to conventional therapies, resulting in significantly worse prognoses compared to other lung cancer types, with a survival time of approximately 4–7 months [10].